Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Sjogren S Syndrome

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43881   clinical trials with a EudraCT protocol, of which   7295   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    47 result(s) found for: Sjogren S Syndrome. Displaying page 1 of 3.
    1  2  3  Next»
    EudraCT Number: 2014-003140-12 Sponsor Protocol Number: LEF-HCQinpSS Start Date*: 2015-09-21
    Sponsor Name:UMC Utrecht
    Full Title: Optimizing DMARD-therapy for primary Sjogren's Syndrome - Leflunomide and Hydroxychloroquine combination therapy for patients with primary Sjogren's Syndrome
    Medical condition: Sjogren's Syndrome
    Disease: Version SOC Term Classification Code Term Level
    18.0 10028395 - Musculoskeletal and connective tissue disorders 10040766 Sjogren's disease LLT
    18.0 10028395 - Musculoskeletal and connective tissue disorders 10040767 Sjogren's syndrome PT
    18.0 10028395 - Musculoskeletal and connective tissue disorders 10042846 Syndrome Sjogren's LLT
    18.0 10028395 - Musculoskeletal and connective tissue disorders 10040765 Sjogren's LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2016-001948-19 Sponsor Protocol Number: IM101-603 Start Date*: 2017-02-02
    Sponsor Name:Bristol-Myers Squibb International Corporation
    Full Title: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Subcutaneous Abatacept in Adults with Active Primary Sjögrens Syndrome
    Medical condition: Adults with moderately to severely Active Primary Sjögrens Syndrome
    Disease: Version SOC Term Classification Code Term Level
    20.0 10028395 - Musculoskeletal and connective tissue disorders 10040766 Sjogren's disease LLT
    20.0 10028395 - Musculoskeletal and connective tissue disorders 10040767 Sjogren's syndrome PT
    20.0 10028395 - Musculoskeletal and connective tissue disorders 10042846 Syndrome Sjogren's LLT
    20.0 10028395 - Musculoskeletal and connective tissue disorders 10040765 Sjogren's LLT
    20.1 10010331 - Congenital, familial and genetic disorders 10048676 Sjogren-Larsson syndrome PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Prematurely Ended) CZ (Prematurely Ended) FR (Prematurely Ended) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2007-003537-16 Sponsor Protocol Number: PR3084 Start Date*: 2008-09-04
    Sponsor Name:Erasmus MC
    Full Title: Estetrol Therapy in Sjogren's Syndrome: An Open Proof of Concept Study
    Medical condition: Primary Sjogren's Syndrome
    Disease: Version SOC Term Classification Code Term Level
    9.1 10040767 Sjogren's syndrome LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2016-000101-37 Sponsor Protocol Number: IM128-035 Start Date*: 2017-04-07
    Sponsor Name:Bristol-Myers Squibb International Corporation
    Full Title: A Phase II, Randomized, Multi-Center, Double-Blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of BMS-931699 (lulizumab) or BMS-986142 in Subjects with Moderate to Severe Primary ...
    Medical condition: subjects with moderate to severe Sjögren's syndrome
    Disease: Version SOC Term Classification Code Term Level
    19.1 10028395 - Musculoskeletal and connective tissue disorders 10040766 Sjogren's disease LLT
    19.1 10028395 - Musculoskeletal and connective tissue disorders 10040767 Sjogren's syndrome PT
    19.1 10028395 - Musculoskeletal and connective tissue disorders 10042846 Syndrome Sjogren's LLT
    19.1 10028395 - Musculoskeletal and connective tissue disorders 10040765 Sjogren's LLT
    19.1 10010331 - Congenital, familial and genetic disorders 10048676 Sjogren-Larsson syndrome PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GR (Completed) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2005-004740-31 Sponsor Protocol Number: Start Date*: 2005-12-21
    Sponsor Name:University of Copenhagen
    Full Title: Efficacy of B-cell depletion with rituximab on oral, ocular and general disease manifestations in patients with primary Sjögren disease
    Medical condition: Previously treated patients with primary Sjögrens disease
    Disease: Version SOC Term Classification Code Term Level
    8.0 10040767 PT
    Population Age: Adults Gender: Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2014-004523-51 Sponsor Protocol Number: SS0004 Start Date*: 2015-05-18
    Sponsor Name:UCB Celltech, UK
    Full Title: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PROOF-OF-CONCEPT STUDY TO EVALUATE THE EFFICACY AND SAFETY OF UCB5857 OVER 12 WEEKS IN SUBJECTS WITH PRIMARY SJOGREN’S SYNDROME
    Medical condition: Primary Sjogren’s Syndrome
    Disease: Version SOC Term Classification Code Term Level
    19.1 10028395 - Musculoskeletal and connective tissue disorders 10040767 Sjogren's syndrome PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended) ES (Prematurely Ended) FR (Completed) SE (Completed) GR (Prematurely Ended) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2014-003896-41 Sponsor Protocol Number: D5181C00001 Start Date*: 2015-03-27
    Sponsor Name:MedImmune, LLC
    Full Title: A Phase 2a, Randomized, Placebo-controlled, Proof of Mechanism Study to Evaluate the Safety and Efficacy of AMG 557/MEDI5872 in Subjects with Primary Sjogren’s Syndrome
    Medical condition: Primary Sjogren’s Syndrome
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004859 10042846 Syndrome Sjogren's LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) SE (Completed)
    Trial results: View results
    EudraCT Number: 2014-004616-12 Sponsor Protocol Number: CCDZ173X2203 Start Date*: 2016-05-20
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A randomized, double-blind, placebo-controlled, parallel group study to assess the safety, tolerability, pharmacokinetics and preliminary efficacy of CDZ173 in patients with primary Sjögren’s syndrome
    Medical condition: Primary Sjögren's syndrome
    Disease: Version SOC Term Classification Code Term Level
    19.0 10028395 - Musculoskeletal and connective tissue disorders 10040767 Sjogren's syndrome PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) HU (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2020-001526-59 Sponsor Protocol Number: CL2-95011-001 Start Date*: 2020-10-20
    Sponsor Name:Institut de Recherches Internationales Servier
    Full Title: A phase IIa efficacy and safety trial with intravenous S95011 in primary Sjögren’s Syndrome patients. An international, multicentre, randomised, double-blind, placebo-controlled study
    Medical condition: Primary Sjögren’s Syndrome
    Disease: Version SOC Term Classification Code Term Level
    21.0 10028395 - Musculoskeletal and connective tissue disorders 10040767 Sjogren's syndrome PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) HU (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2021-005911-30 Sponsor Protocol Number: ARGX-113-2106 Start Date*: 2022-12-27
    Sponsor Name:argenx BV
    Full Title: A Phase 2, Randomized, Placebo-controlled, Parallel Group, Double-blind, Proof-of-concept Study to Evaluate the Safety and Efficacy of Intravenous Efgartigimod in Adult Participants With Primary Sj...
    Medical condition: Primary Sjögren’s Syndrome
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004859 10042846 Syndrome Sjogren's LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed) HU (Completed)
    Trial results: (No results available)
    EudraCT Number: 2021-000665-32 Sponsor Protocol Number: 80202135SJS2001 Start Date*: 2021-11-12
    Sponsor Name:Janssen-Cilag International NV
    Full Title: A Randomized, Placebo-controlled, Double-blind, Multicenter Study to Assess the Efficacy and Safety of Nipocalimab in Adults with Primary Sjogren's Syndrome (pSS)
    Medical condition: Primary Sjogren's Syndrome
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004859 10040766 Sjogren's disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) ES (Ongoing) IT (Ongoing) PL (Completed) PT (Completed) NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2013-000250-22 Sponsor Protocol Number: CVAY736X2201 Start Date*: 2014-04-11
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A single dose, double-blind, placebo-controlled, parallel study to assess the pharmacodynamics, pharmacokinetics and safety and tolerability of VAY736 in patients with primary Sjögren’s syndrome
    Medical condition: Seropositive primary Sjögren’s syndrome
    Disease: Version SOC Term Classification Code Term Level
    19.0 10028395 - Musculoskeletal and connective tissue disorders 10040767 Sjogren's syndrome PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2020-003298-22 Sponsor Protocol Number: GLPG3970-CL-207 Start Date*: 2021-01-15
    Sponsor Name:Galapagos NV
    Full Title: A randomized, double-blind, placebo-controlled, multicenter study to evaluate the efficacy, safety, tolerability, pharmacokinetics and pharmacodynamics of orally administered GLPG3970 for 12 weeks ...
    Medical condition: Primary Sjogren's Syndrome
    Disease: Version SOC Term Classification Code Term Level
    21.0 10028395 - Musculoskeletal and connective tissue disorders 10040767 Sjogren's syndrome PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Prematurely Ended) DE (Prematurely Ended) HU (Completed) GR (Completed) ES (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2020-001942-20 Sponsor Protocol Number: CCFZ533B2201E1 Start Date*: 2020-11-16
    Sponsor Name:Novartis Pharma AG
    Full Title: A TWINSS extension trial to evaluate the safety and tolerability of CFZ533 (iscalimab) at two dose levels administered subcutaneously in patients with Sjögren’s Syndrome
    Medical condition: Sjögren syndrome
    Disease: Version SOC Term Classification Code Term Level
    21.0 10028395 - Musculoskeletal and connective tissue disorders 10040767 Sjogren's syndrome PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) GR (Completed) DE (Completed) PT (Completed) FR (Completed) NL (Ongoing) IT (Ongoing) SE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-005055-20 Sponsor Protocol Number: CVAY736A2103 Start Date*: 2022-04-25
    Sponsor Name:Novartis Pharma AG
    Full Title: An open-label, non-randomized, biopsy-based mechanistic study on efficacy, pharmacokinetics, pharmacodynamics, safety and tolerability of ianalumab in patients with Sjögren's syndrome
    Medical condition: Sjögren's syndrome
    Disease: Version SOC Term Classification Code Term Level
    21.0 10028395 - Musculoskeletal and connective tissue disorders 10040767 Sjogren's syndrome PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2021-003346-21 Sponsor Protocol Number: NGF0121 Start Date*: 2021-11-24
    Sponsor Name:DOMPé FARMACEUTICI S.P.A.
    Full Title: A 4 week, Phase III, multicenter, double-masked, vehicle-controlled study to evaluate safety and efficacy of Oxervate® (cenegermin) 20 mcg/mL ophthalmic solution versus vehicle, in patients with se...
    Medical condition: Severe Sjogren’s dry eye disease
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004859 10040766 Sjogren's disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2014-000417-31 Sponsor Protocol Number: IM101-473 Start Date*: 2014-07-01
    Sponsor Name:University Medical Center Groningen
    Full Title: Randomized, double-blind, placebo-controlled phase III study (ASAP III study) to assess the efficacy and safety of Abatacept treatment in patients with primary Sjögren’s syndrome (ASAP III study = ...
    Medical condition: Primary Sjögren's syndrome (pSS)
    Disease: Version SOC Term Classification Code Term Level
    16.1 100000004859 10042846 Syndrome Sjogren's LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2009-015558-40 Sponsor Protocol Number: ABACEPT1 Start Date*: 2010-07-28
    Sponsor Name:University Medical Center Groningen
    Full Title: Abatacept treatment in patients with primary Sjögren’s syndrome
    Medical condition: Sjögren’s syndrome (SS) is a chronic, systemic, lymphoproliferative autoimmune disease affecting the exocrine glands. The salivary and lacrimal glands are most commonly affected, resulting in dry m...
    Disease: Version SOC Term Classification Code Term Level
    12.0 10040767 Sjogren's syndrome LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2015-004476-30 Sponsor Protocol Number: BP30037 Start Date*: 2016-06-22
    Sponsor Name:F. Hoffmann-La Roche Ltd
    Full Title: A MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROUP PHASE 2A STUDY TO ASSESS THE EFFICACY OF RO5459072 IN PATIENTS WITH PRIMARY SJÖGREN’S SYNDROME
    Medical condition: Primary Sjögren’s syndrome
    Disease: Version SOC Term Classification Code Term Level
    19.0 10028395 - Musculoskeletal and connective tissue disorders 10040767 Sjogren's syndrome PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) PT (Completed) DE (Completed) PL (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2009-013976-38 Sponsor Protocol Number: COLO400BDE02T Start Date*: Information not available in EudraCT
    Sponsor Name:Charité Berlin, Department of rheumatology [...]
    1. Charité Berlin, Department of rheumatology
    2. Charité Berlin, department of rheumatology
    3. Charité Berlin, department of rheumatology
    Full Title: Phase II Trial of low-dose Sandimmun Optoral ® (Cyclosporine A) for the treatment of primary Sjögren's syndrome (pSS)
    Medical condition: Primary Sjögren's Syndrome
    Disease: Version SOC Term Classification Code Term Level
    12.1 10059142 Sjoegren's syndrome LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sun May 19 23:01:50 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA